Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Astellas' Xtandi to challenge J&J's Zytiga in the EU with pre-chemo OK

After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.

J&J looks for Xarelto boost in real-world cost data

These days, sometimes it's not enough to prove your drug is more effective than the standard of care. As rising drug costs continue to trigger concerns and pushback among payers, providers and patients, it's not a bad idea to prove your drug can beat the old guard on cost--or at the very least, match it. And that's just what Johnson & Johnson's Janssen unit says it's done with Xarelto.

J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III

Johnson & Johnson is walking away from a potential rheumatoid arthritis treatment from Astellas, nixing a deal that could have paid out at $945 million and putting the drug's stateside future in jeopardy.

FDA approves Animas insulin pump, continuous glucose monitor combo device

The U.S. Food and Drug Administration has approved the Animas Vibe, a combination insulin pump and continuous glucose monitor. It allows patients with Type 1 diabetes to monitor blood glucose levels and adjust insulin delivery based on that data.

J&J bets up to $277M on a prospect from its R&D farm system

Johnson & Johnson's plan to grow its pipeline with deal-scouting outposts around the globe is beginning to pay off, as the drugmaker's London lookout has brought in what could be a promising approach to rheumatoid arthritis.

J&J hopes third time is the charm for antitumor agent Yondelis

Five years after the FDA formally rejected J&J's Yondelis (trabectedin) for ovarian cancer, and three years after an aborted effort to get it back on track, the pharma giant has finally made its way back to the agency for another try at an approval--this time as a treatment for soft tissue sarcoma.

UPDATED: J&J jumps into hot CAR-T field with gene-editing experts at Transposagen

Johnson & Johnson is following in the footsteps of pioneers like Novartis, Celgene and GlaxoSmithKline, inking a discovery-stage development deal--but turning to the little-known Transposagen Biopharmaceuticals to make its entry.

Boston Scientific and J&J gear up for courtroom showdown over Guidant purchase

Boston Scientific and Johnson & Johnson are gearing up for a courtroom showdown, as the companies prepare for a multibillion-dollar trial over a breach-of-contract suit related to a failed bidding war for devicemaker Guidant.

Texas judge tosses out 76 suits in J&J's ongoing vaginal mesh litigation

Johnson & Johnson's Ethicon unit scored a victory in its ongoing vaginal mesh litigation as a federal judge in Texas tossed out 76 liability lawsuits related to the company's pelvic mesh devices.

Brain tumor treatment device gets early trial halt for efficacy as a combo with chemo

The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.